Publications en collaboration avec des chercheurs de Copenhagen University Hospital (96)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  3. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  5. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 7, pp. 1891-1908

  6. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

    Blood, Vol. 144, Núm. 8, pp. 873-887

  7. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol

    Journal of Headache and Pain, Vol. 25, Núm. 1

  8. Global cross-sectional survey on neonatal pharmacologic sedation and analgesia practices and pain assessment tools: impact of the sociodemographic index (SDI)

    Pediatric Research

  9. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock

    New England Journal of Medicine, Vol. 390, Núm. 15, pp. 1382-1393

  10. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology

  11. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  12. Parents in Neonatal Pain Management—An International Survey of Parent-Delivered Interventions and Parental Pain Assessment

    Children, Vol. 11, Núm. 9

  13. Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic

    Archives of Gynecology and Obstetrics, Vol. 310, Núm. 1, pp. 577-586

  14. Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation: The PURPOSE Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 13, pp. 1597-1606

  15. Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project

    Cardiovascular Revascularization Medicine

  16. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe

    International Journal of Gynecological Cancer

  17. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

    Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029

  18. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701

  19. Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up

    The Lancet, Vol. 404, Núm. 10457, pp. 1019-1028

2023

  1. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

    Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229